Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Are the Projected Market Size and Growth Rates for the Opdivo (nivolumab) Market From 2025 To 2029?
There has been significant growth in the size of the opdivo (nivolumab) market in recent times. The predicted growth is from $7,709.49 million in 2024 to $8,335.54 million in 2025, experiencing a compound annual growth rate (CAGR) of 8.1%. The historical growth can be credited to the increasing cases of cancer, the amplification in funds for research and development capabilities, more investment in healthcare infrastructure, a rise in cases of non-small lung cancer, and an increase in healthcare capital expenditure.
What Is the Projected Market Size of the Opdivo (nivolumab) Market?
An impressive expansion is anticipated for the opdivo (nivolumab) market in the coming years, with projections suggesting growth to $11,281.56 million in 2029, demonstrating a compound annual growth rate (CAGR) of 7.9%. Factors enabling this significant growth during the forecast period include the rising approval of immunotherapy, a growing comprehension of immunotherapy along with its associated benefits, an increase in healthcare spending specifically for capital equipment, the growing applicability of nivolumab for various indicators, and a heightened inclination towards immunotherapy treatments. In terms of the major trends during the forecast period, they encompass product novelty, market expansion into new geographical territories, ongoing clinical experimentations, an increasing shift towards tailored medical treatment, and breakthroughs in cancer study.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=19914&type=smp
Who are the Major Competitors in the Opdivo (nivolumab) Market Outlook?
Major companies operating in the opdivo (nivolumab) market include Bristol-Myers Squibb, Ono Pharmaceutical
What Is Fueling Growth in the Opdivo (nivolumab) Market?
The rising prevalence of non-small lung cancer is projected to stimulate the expansion of the opdivo (nivolumab) market in the future. Non-small cell lung cancer (NSCLC), contributing to around 85% of all lung cancers, is the most prevalent variety. Various factors are mainly responsible for the escalating occurrence of NSCLC, including smoking habits, genetic mutations, exposure to environmental pollutants, and history of cancer within the family. Opdivo acts by obstructing the PD-1 receptor present on immune cells, subsequently augmenting the body’s immune response to identify and combat cancer cells. For instance, in 2024, the American Cancer Society, a health organization based in the US, confirmed that there were 234,580 fresh lung cancer cases diagnosed in the US, out of which 80% were NSCLC, exhibiting a rise from 2023, when 238,340 individuals were diagnosed with lung cancer. Hence, the escalating prevalence of non-small lung cancer is contributing considerably to the growth of the opdivo (nivolumab) market.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=19914&type=smp
Which Opdivo (nivolumab) Market Segments Are Growing the Fastest?
The opdivo (nivolumab)market covered in this report is segmented –
1) By Type: 40 mg/4 mL; 100 mg/10 mL; 240 mg/24 mL
2) By Dosage: Injection; Solution; Other Dosages
3) By Demographic: Adult; Pediatric
4) By Application: Melanoma; Non-small Cell Lung Cancer (NSCLC); Malignant Pleural Mesothelioma; Classical Hodgkin Lymphoma (CHL); Squamous Cell Carcinoma of the Head and Neck (SCCHN); Renal Cell Carcinoma (RCC); Other Applications
5) By End-User: Hospitals; Clinics; Other End Users
Which Industry Trends Are Shaping the Future of the Opdivo (nivolumab) Market?
The prevailing trend in the Opdivo (nivolumab) market revolves around the progression of combination therapies. The goal is to improve the effectiveness of the treatment and broadening its use across various types of cancer. The strategy is to address resistance mechanisms and broaden treatment options for advanced cancer patients. In October 2024, Opdivo (nivolumab) combined with platinum-doublet chemotherapy was granted approval by the United States Food and Drug Administration for neoadjuvant treatment. This was to be followed by the usage of single-agent nivolumab post-surgery as adjuvant treatment for adults with resectable non-small cell lung cancer. Additionally, the approval paves the way for using Opdivo in conjunction with platinum-doublet chemotherapy before surgery and as a monotherapy following surgery for patients lacking known EGFR or ALK mutations.
Access The Full Report Here:
https://www.thebusinessresearchcompany.com/report/opdivo-nivolumab-global-market-report-
Which Countries Are Leading the Opdivo (nivolumab) Market?
North America was the largest region in the 0pdivo (nivolumab) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the opdivo (nivolumab) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=19914
This Report Delivers Insight On:
1. How big is the opdivo (nivolumab) market, and how is it changing globally?
2. Who are the major companies in the opdivo (nivolumab) market, and how are they performing?
3. What are the key opportunities and risks in the opdivo (nivolumab) market right now?
4. Which products or customer segments are growing the most in the opdivo (nivolumab) market?
5. What factors are helping or slowing down the growth of the opdivo (nivolumab) market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 2071930708
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model